Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03703908 · ClinicalTrials.gov registry record · Phase 2
A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome
A Phase 2 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03703908 is a Phase 2 study that was terminated before completion, run by Amgen. The registered enrollment target is 5 participants.
The verdict
NCT03703908, a Phase 2 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
An Open Label, Intra-Subject Dose Escalation Study of CCX140 B in Subjects with Primary FSGS and Nephrotic Syndrome
Interventions
- DRUG CCX140-B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2020-06-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03703908
The ClinicalTrials.gov registry entry for NCT03703908 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CCX140-B is the first listed.
NCT03703908 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03703908 about?
NCT03703908 is a clinical study titled "A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome". An Open Label, Intra-Subject Dose Escalation Study of CCX140 B in Subjects with Primary FSGS and Nephrotic Syndrome
What is the current status of trial NCT03703908?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2018-10-01. Estimated completion is 2020-06-24.
What interventions are being tested in trial NCT03703908?
The interventions under investigation include: CCX140-B (DRUG).
Who is sponsoring clinical trial NCT03703908?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.